| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
24,140,000 |
| Market
Cap: |
665.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$26.52 - $75.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
652,175 |
| Total Buy Value |
$0 |
$0 |
$0 |
$15,000,025 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
28,717 |
1,809,244 |
3,899,666 |
3,922,166 |
| Total Sell Value |
$2,003,947 |
$108,294,855 |
$210,108,656 |
$210,155,681 |
| Total People Sold |
2 |
8 |
12 |
13 |
| Total Sell Transactions |
2 |
33 |
51 |
52 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  White William Richard |
|
– • – |
2024-04-11 |
4 |
AS |
$31.79 |
$81,407 |
D/D |
(2,560) |
0 |
|
-14% |
|
| White William Richard |
|
– • – |
2024-04-11 |
4 |
OE |
$2.65 |
$12,581 |
D/D |
2,560 |
2,560 |
|
- |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2024-04-10 |
4 |
OE |
$2.65 |
$57,956 |
D/D |
21,870 |
43,405 |
|
- |
|
| Bitterman Kevin |
|
– • – |
2024-03-05 |
4 |
S |
$73.50 |
$1,922,540 |
I/I |
(26,157) |
677,503 |
|
62% |
|
| Stephenson Pamela |
Chief Commercial Officer |
• – – |
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
36,666 |
36,666 |
|
- |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
36,666 |
36,666 |
|
- |
|
| Atlas Venture Associates Opportunity Ii, Llc |
10% Owner |
– – • |
2024-01-23 |
4 |
S |
$67.65 |
$6,934,125 |
I/I |
(102,500) |
198,326 |
|
60% |
|
| Atlas Venture Associates Opportunity Ii, Llc |
10% Owner |
– – • |
2024-01-23 |
4 |
S |
$67.65 |
$3,213,375 |
D/D |
(47,500) |
1,402,186 |
|
60% |
|
| Bitterman Kevin |
Director |
– • – |
2024-01-23 |
4 |
S |
$67.65 |
$6,934,125 |
I/I |
(102,500) |
198,326 |
|
60% |
|
| Yu Jonathan Yen-Wen |
Chief Business Officer |
• – – |
2024-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,165 |
18,165 |
|
- |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2024-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,535 |
21,535 |
|
- |
|
| Bryce Joanne |
Chief Financial Officer |
• – – |
2024-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
18,165 |
23,665 |
|
- |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2024-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
66,365 |
69,065 |
|
- |
|
| Khara Rahul |
General Counsel |
• – – |
2024-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
14,035 |
14,035 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-10 |
4 |
S |
$64.00 |
$1,280,000 |
I/I |
(20,000) |
786,160 |
|
59% |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-10 |
4 |
S |
$64.00 |
$1,920,000 |
D/D |
(30,000) |
1,449,686 |
|
59% |
|
| Bitterman Kevin |
Director |
– • – |
2024-01-10 |
4 |
S |
$64.00 |
$1,280,000 |
I/I |
(20,000) |
786,160 |
|
59% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2023-12-29 |
4 |
OE |
$1.01 |
$2,727 |
D/D |
2,700 |
2,700 |
|
- |
|
| Bryce Joanne |
Chief Financial Officer |
• – – |
2023-12-27 |
4 |
OE |
$9.86 |
$29,580 |
D/D |
3,000 |
5,500 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2023-12-18 |
4 |
S |
$59.24 |
$102,130 |
D/D |
(1,724) |
0 |
|
55% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2023-12-18 |
4 |
OE |
$38.00 |
$65,512 |
D/D |
1,724 |
1,724 |
|
- |
|
| Ashiya Mona |
Director |
– • – |
2023-12-18 |
4 |
S |
$59.24 |
$102,130 |
D/D |
(1,724) |
0 |
|
55% |
|
| Ashiya Mona |
Director |
– • – |
2023-12-18 |
4 |
OE |
$38.00 |
$65,512 |
D/D |
1,724 |
1,724 |
|
- |
|
| Ashiya Mona |
Director |
– • – |
2023-12-14 |
4 |
S |
$56.75 |
$24,584,100 |
I/I |
(433,200) |
224,405 |
|
54% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2023-12-14 |
4 |
S |
$56.75 |
$24,584,100 |
I/I |
(433,200) |
224,405 |
|
54% |
|
115 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.03 (3.88%) 
